Cargando…

Optimizing bronchodilation in the prevention of COPD exacerbations

The natural disease course of chronic obstructive pulmonary disease (COPD) is often punctuated by exacerbations: acute events of symptom worsening associated with significant morbidity and healthcare resource utilization; reduced quality of life; and increased risk of hospitalization and death. The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miravitlles, Marc, Anzueto, Antonio, Jardim, José R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477752/ https://www.ncbi.nlm.nih.gov/pubmed/28633665 http://dx.doi.org/10.1186/s12931-017-0601-2

Ejemplares similares

The role of bronchodilator treatment in the prevention of exacerbations of COPD
por: Wedzicha, Jadwiga A., et al.
Publicado: (2012)

When is dual bronchodilation indicated in COPD?
por: Thomas, Mike, et al.
Publicado: (2017)

Stepwise management of COPD: What is next after bronchodilation?
por: Miravitlles, Marc, et al.
Publicado: (2023)

Optimal Bronchodilation for COPD Patients: Are All Long-Acting β(2)-Agonist/Long-Acting Muscarinic Antagonists the Same?
por: Miravitlles, Marc, et al.
Publicado: (2018)

Insights into interventions in managing COPD patients: lessons from the TORCH and UPLIFT(®) studies
por: Miravitlles, Marc, et al.
Publicado: (2009)

Early response to inhaled bronchodilators and corticosteroids as a predictor of 12-month treatment responder status and COPD exacerbations
por: Calverley, Peter M, et al.
Publicado: (2016)

Bronchodilators in COPD: Impact of β-agonists and anticholinergics on severe exacerbations and mortality
por: Salpeter, Shelley R
Publicado: (2007)

The Importance of Inhaler Adherence to Prevent COPD Exacerbations
por: Jardim, Jose R., et al.
Publicado: (2019)

Prognostic factors for clinical failure of exacerbations in elderly outpatients with moderate-to-severe COPD
por: Wilson, Robert, et al.
Publicado: (2015)

Moxifloxacin in the management of exacerbations of chronic bronchitis and COPD
por: Miravitlles, Marc
Publicado: (2007)

Impact and prevention of severe exacerbations of COPD: a review of the evidence
por: Halpin, David MG, et al.
Publicado: (2017)

COPD: maximization of bronchodilation
por: Nardini, Stefano, et al.
Publicado: (2014)

A novel study design for antibiotic trials in acute exacerbations of COPD: MAESTRAL methodology
por: Wilson, Robert, et al.
Publicado: (2011)

Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results
por: Wilson, Robert, et al.
Publicado: (2012)

The Role of Bronchodilators in Preventing Exacerbations of Chronic Obstructive Pulmonary Disease
por: Beeh, Kai M.
Publicado: (2016)

Time To Revise COPD Treatment Algorithm
por: Matsunaga, Kazuto, et al.
Publicado: (2019)

Which bronchodilator in COPD?
por: Russell, Richard, et al.
Publicado: (2007)

Impact of bronchodilator therapy on exercise tolerance in COPD
por: Aguilaniu, B
Publicado: (2010)

Flow and volume response to bronchodilator in patients with COPD
por: Matteo, Vigna, et al.
Publicado: (2018)

Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review
por: Miravitlles, Marc, et al.
Publicado: (2016)

Bronchodilators use in patients with COPD
por: Dong, Yaa-Hui, et al.
Publicado: (2015)

The need to further understand who gets hospitalized for a COPD exacerbation
por: Maselli, Diego J, et al.
Publicado: (2012)

Chronic Respiratory Infection in Patients with Chronic Obstructive Pulmonary Disease: What Is the Role of Antibiotics?
por: Miravitlles, Marc, et al.
Publicado: (2017)

Tiotropium in chronic obstructive pulmonary disease – a review of clinical development
por: Anzueto, Antonio, et al.
Publicado: (2020)

Future concepts in bronchodilation for COPD: dual- versus monotherapy
por: Singh, Dave, et al.
Publicado: (2021)

A Pooled Analysis of Mortality in Patients with COPD Receiving Dual Bronchodilation with and without Additional Inhaled Corticosteroid
por: Miravitlles, Marc, et al.
Publicado: (2022)

Factors associated with change in exacerbation frequency in COPD
por: Donaldson, Gavin C, et al.
Publicado: (2013)

Striving for optimal bronchodilation: focus on olodaterol
por: Incorvaia, Cristoforo, et al.
Publicado: (2016)

Treatment of exacerbations as a predictor of subsequent outcomes in patients with COPD
por: Calverley, Peter MA, et al.
Publicado: (2018)

Update on Asthma–COPD Overlap (ACO): A Narrative Review
por: Mekov, Evgeni, et al.
Publicado: (2021)

Determinants of exacerbation risk in patients with COPD in the TIOSPIR study
por: Calverley, Peter MA, et al.
Publicado: (2017)

COPD exacerbations: defining their cause and prevention
por: Wedzicha, Jadwiga A, et al.
Publicado: (2007)

Data Reproducibility and Effectiveness of Bronchodilators for Improving Physical Activity in COPD Patients
por: Minakata, Yoshiaki, et al.
Publicado: (2020)

Severe COPD Exacerbation Risk and Long-Acting Bronchodilator Treatments: Comparison of Three Observational Data Analysis Methods
por: Roberts, Melissa H., et al.
Publicado: (2015)

Optimizing antibiotic selection in treating COPD exacerbations
por: Siddiqi, Attiya, et al.
Publicado: (2008)

Impact of frequency of COPD exacerbations on pulmonary function, health status and clinical outcomes
por: Anzueto, A, et al.
Publicado: (2009)

Therapeutic Success in Swiss COPD Patients Receiving Dual Bronchodilation Therapy as COPD Maintenance Treatment
por: Spielmanns, Marc, et al.
Publicado: (2022)

The future of bronchodilation: looking for new classes of bronchodilators
por: Cazzola, Mario, et al.
Publicado: (2019)

Use of Computed Tomography Lung Densitometry as an Outcome Measure for Emphysema Progression: The Case of Losartan
por: Miravitlles, Marc, et al.
Publicado: (2022)

Patient-reported outcomes of dual bronchodilator fixed-dose combination versus bronchodilator monotherapy in individuals with COPD
por: Strange, Charlie, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ntuh7ql7k0d92qscn9v4pbg244